ProShares UltraShort Bloomberg Natural Gas ETF vs Vaxcyte Inc. Common Stock — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.11 (market cap $140.85M), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 74.6× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| KOLD | PCVX | |
|---|---|---|
Market Cap | $140.85M | $10.51B |
Volume | 4,297,516 | 2,644,694 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $73.82 |
52-Week Low | $13.58 | $40.32 |
Typical Hold Time | 10 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $23.85, down 5.06% over the past 24 hours amid bearish technical signals. The stock shows significant selling pressure with 16 sell signals versus 1 buy signal across technical indicators. Natural gas market fundamentals remain challenging with record-high U.S. production reported by the EIA in July 2026, while geopolitical tensions in the Middle East create volatility in energy markets.
The outlook remains cautious as technical indicators point to continued downward momentum. Investment opportunities exist for contrarian investors given the oversold RSI reading, but risks include persistent natural gas price weakness and high production levels that may pressure energy sector performance in the near term.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →